This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
== Superintendent/CEO == In 2013, a governance reorganization led by then-County Executive Rushern Baker renamed the superintendent position to chief executive officer of PGCPS. Dubbed a 'takeover' of the county's school system, this shift increased the operational control for the CEO while limiting the school board's powers. Dr. Kevin Maxwell was the inaugural CEO of Prince George's County Public Schools, serving until 2018. He was succeeded by Dr. Monica Goldson, who remained in the position through the 2022–23 school year. After a rigorous 6-month nationwide search, the district shortlisted three candidates. Following an interview with County Executive Angela Alsobrooks, Millard House II, former Superintendent of the Houston Independent School District, was chosen to succeed Dr. Goldson. With House's appointment as Superintendent in June 2023, the district ceased referring to its head as CEO. Dr. Shawn Joseph was appointed interim superintendent for the 2025–2026 school year. On June 1, 2026, the appointment of Dr. Joseph to the Superintendent role was made permanent.
=== Etymology === The word "mesentery" and its Neo-Latin equivalent mesenterium () use the combining forms mes- + enteron, ultimately from ancient Greek μεσέντερον (mesenteron), from μέσος (mésos, "middle") + ἔντερον (énteron, "gut"), yielding "mid-intestine" or "midgut". The adjectival form is "mesenteric" ().
In the case of Cu3(BTC)2 the morphology of the solvent free synthesised product was the same as the industrially made Basolite C300. It is thought that localised melting of the components due to the high collision energy in the ball mill may assist the reaction. The formation of acetic acid as a by-product in the reactions in the ball mill may also help in the reaction having a solvent effect in the ball mill. It has been shown that the addition of small quantities of ethanol for the mechanochemical synthesis of Cu3(BTC)2 significantly reduces the amounts of structural defects in the obtained material. A recent advancement in the solvent-free preparation of MOF films and composites is their synthesis by chemical vapor deposition. This process, MOF-CVD, was first demonstrated for ZIF-8 and consists of two steps. In a first step, metal oxide precursor layers are deposited. In the second step, these precursor layers are exposed to sublimed ligand molecules, that induce a phase transformation to the MOF crystal lattice. Formation of water during this reaction plays a crucial role in directing the transformation. This process was successfully scaled up to an integrated cleanroom process, conforming to industrial microfabrication standards. Numerous methods have been reported for the growth of MOFs as oriented thin films. However, these methods are suitable only for the synthesis of a small number of MOF topologies. One such example being the vapor-assisted conversion (VAC) which can be used for the thin film synthesis of several UiO-type MOFs.
Sources: en.wikipedia.org
Potatoes Sweet potatoes Tomatoes Onions and Cabbage In 2013 global fruit production was estimated at 676.9 million tonnes (666,200,000 long tons; 746,200,000 short tons). Global vegetable production (including melons) was estimated at 879.2 million tonnes (865,300,000 long tons; 969,200,000 short tons) with China and India being the two top producing countries.
Vitiligo ( VIT-ih-LY-goh) is a chronic autoimmune disorder that causes skin to lose pigment (specifically melanin, which gives the skin color) in patches that vary in size and can appear anywhere on the body. The development of vitiligo is linked to aberrant attachments between melanocytes (which produce melanin) and laminins, an extracellular protein. The disorder is thought to be caused by immune system changes with potential genetic factors. Often first appearing by young adulthood, it may be triggered by environmental factors, sun or chemical exposure, stress, and physical trauma. The most common form tends to affect more skin over time. Potential treatments include topical immunosuppressants and ultraviolet light therapy, especially 311-nm UVB in combination with antioxidants. In antiquity, the disorder was often conflated with leprosy, an infectious disease. Some public figures have had vitiligo, such as the singer Michael Jackson, who obscured his condition until it affected his entire body.
The carpal bones and the transverse carpal ligament form the carpal tunnel. The median nerve passes through this space along with the flexor tendons. Increased compartmental pressure for any reason can squeeze the median nerve. Theoretically, increased pressure can interfere with normal intraneural blood flow, eventually causing a cascade of physiological changes in the nerve itself. There is a dose-respondent curve such that greater and longer periods of pressure are associated with greater nerve dysfunction. The symptoms and signs of carpal tunnel syndrome causes are hypertrophy of the synovial tissue surrounding the flexor tendons such as with rheumatoid arthritis. Prolonged pressure can lead to a cascade of physiological changes in neural tissue. First, the blood-nerve barrier breaks down (increased permeability of perineureum and endothelial cells of endoneural blood vessels). If the pressure continues, the nerves will start the process of demyelination under the area of compression. This will result in abnormal nerve conduction even when the pressure is relieved leading to persistent sensory symptoms until remyelination can occur. If the compression continues and is severe enough, axons may be injured and Wallerian degeneration will occur. At this point there may be weakness and muscle atrophy, depending on the extent of axon damage. The critical pressure above which the microcirculatory environment of a nerve becomes compromised depends on diastolic/systolic blood pressure.
Sources: en.wikipedia.org
BCG vaccine Cholera vaccine Dengue vaccine Diphtheria vaccine Ebola vaccine Haemophilus influenzae type b vaccine Hepatitis A vaccine Hepatitis B vaccine Hepatitis E vaccine Human papilloma virus (HPV) vaccine Influenza vaccine (seasonal) Japanese encephalitis vaccine Malaria vaccine Measles vaccine Meningococcal meningitis vaccine Mpox vaccine Mumps vaccine Pertussis vaccine Pneumococcal vaccine Poliomyelitis vaccine Rabies vaccine Respiratory syncytial virus vaccine Rotavirus vaccine Rubella vaccine Tetanus vaccine Tick-borne encephalitis vaccine Typhoid vaccine Varicella vaccine Yellow fever vaccine
In general, Hydrophobic Interaction Chromatography (HIC) is advantageous if the sample is sensitive to pH change or harsh solvents typically used in other types of chromatography but not high salt concentrations. Commonly, it is the amount of salt in the buffer which is varied. In 2012, Müller and Franzreb described the effects of temperature on HIC using Bovine Serum Albumin (BSA) with four different types of hydrophobic resin. The study altered temperature as to effect the binding affinity of BSA onto the matrix. It was concluded that cycling temperature from 40 to 10 degrees Celsius would not be adequate to effectively wash all BSA from the matrix but could be very effective if the column would only be used a few times. Using temperature to effect change allows labs to cut costs on buying salt and saves money. If high salt concentrations along with temperature fluctuations want to be avoided one can use a more hydrophobic to compete with one's sample to elute it. This so-called salt independent method of HIC showed a direct isolation of Human Immunoglobulin G (IgG) from serum with satisfactory yield and used β-cyclodextrin as a competitor to displace IgG from the matrix. This largely opens up the possibility of using HIC with samples which are salt sensitive as we know high salt concentrations precipitate proteins.
== Formulation types == The drug form varies by its way to be administered into the body called route of administration including oral, sublingual, transdermal and inhalation delivery It can be delivered as capsules, tablets, granules, pills etc.
== Functions == Endorphins play a major role in the body's inhibitory response to pain. Research has demonstrated that meditation by trained individuals can be used to trigger endorphin release. Laughter may also stimulate endorphin production and elevate one's pain threshold. Endorphin production can be triggered by vigorous aerobic exercise. The release of β-endorphin has been postulated to contribute to the phenomenon known as "runner's high". However, experimental blockade of the mu opioid receptor has shown that endorphins are not strictly necessary for the development of exercise-induced euphoria. It has been suggested that other neurotransmitters, namely endocannabinoids, are more likely contributors. Endorphins may partially mediate exercise-induced analgesia.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.